哈空調(600202.SH):控股子公司富山川生物科技發展有限公司沒有合成生物相關技術儲備
格隆匯5月17日丨哈空調(600202.SH)在互動平台表示,2023年,公司進一步開拓國際市場,新增多項國際合同和跨國企業合同;利用新產品、新技術優勢,在老舊電廠改造,節能減排升級上有了重大突破,擁有了多項技術儲備,形成了新建、改造齊頭並進的業務模式。2023年,國際市場(出口)訂貨金額摺合人民幣約33,693.30萬元,較上年增長541.50%。公司控股子公司富山川生物科技發展有限公司沒有合成生物相關技術儲備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.